GRI Bio, Inc. (GRI) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.86

From 52W high−96.95%

Volume111508.00

Market cap$4.22M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.86

From 52W high

−96.95%

Volume

111508.00

Market cap

$4.22M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.6x

P/E (TTM)

—

RSI (14)

48.9

MomentumView details →

1D Return

+4.89%

YTD Return

−73.23%

SummaryUpdated Jun 1, 2026

GRI Bio, Inc. (NASDAQ:GRI) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in La Jolla, California. Originally established as Glycoregimmune, Inc., the company went public in February 2021 and focuses on developing novel therapeutic treatments for inflammatory, fibrotic, and autoimmune diseases. As a clinical-stage biotechnology firm, GRI Bio operates without generating product revenue, instead relying on research and development activities to advance its pipeline of experimental drug candidates through various phases of clinical trials.

Ask drillr about GRI Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−116.30%

ROA (TTM)

−105.06%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+4.89%

YTD Return

−73.23%

1Y Return

−96.35%

RSI (14)

48.9

vs 50D SMA

+6.38%

vs 200D SMA

−60.87%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

10.30x

Quick Ratio

10.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.91

EPS Surprise

23.53%

Beats (12Q)

3/12

Next Q EPS Est

−$0.84

Avg Surprise (4Q)

3.26%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−8.30M

Op. CF (TTM)

−11.79M

Next earningsNov 13, 2026 →

Latest newsMore news →

The U.S. Food and Drug Administration granted Orphan Drug Designation to GRI Bio's drug GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.94d ago

Similar companies

Niki BioSolutions, Inc.NIKI OSR Holdings, Inc.OSRH Mustang Bio, Inc.MBIO Cadrenal Therapeutics, Inc. Common StockCVKD PMGC Holdings Inc.ELAB Liminatus Pharma, Inc. Class A Common StockLIMN Find similar companies →

Latest newsMore news →

GRI Bio announced that three abstracts and an oral presentation highlighting data from its Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society Congress in Barcelona, Spain.27d ago The U.S. Food and Drug Administration granted Orphan Drug Designation to GRI Bio's drug GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.94d ago